Chronic back pain tech gets $20m boost
This article was originally published in Clinica
Executive Summary
Relievant Medsystems is to expand clinical trials of its Intracept minimally-invasive treatment for chronic low back pain later this year, after raising $20m in new capital. The funds came from new investors Morgenthaler Ventures – which led the financing – and Emergent Medical Partners, as well as Relievant's existing shareholders Canaan Partners and ONSET Ventures.